BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $64
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54
Avidity Biosciences (RNA) Gets a Buy From Evercore ISI
Avidity Biosciences Receives Buy Rating on Strong Clinical Results and Strategic Growth Prospects
Avidity Biosciences Earns Buy Rating on Strong Clinical Trial Results for Duchenne Muscular Dystrophy Treatment
Cantor Fitzgerald Keeps Their Buy Rating on Avidity Biosciences (RNA)
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45
Avidity Biosciences Analyst Ratings
Avidity Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA) and Curaleaf Holdings (OtherCURLF)
Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancements
Avidity Biosciences Analyst Ratings
Avidity Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)